NIKKEI 225
37,962.58 -497.50 (-1.29%) HANG SENG
17,201.27 +372.34 (+2.21%) CRUDE OIL
82.65 -0.16 (-0.19%) GOLD FUTURES
2,328.80 -9.60 (-0.41%) DOW
38,460.92 -42.77 (-0.11%) Bitcoin GBP
51,733.18 -1,811.38 (-3.38%)
Ocuphire Pharma, Inc. (R3X1.F)
| Previous close | 1.4120 |
| Open | 1.4140 |
| Bid | 1.4060 x N/A |
| Ask | 1.4620 x N/A |
| Day's range | 1.3900 - 1.4160 |
| 52-week range | 1.3900 - 6.0100 |
| Volume | |
| Avg. volume | 130 |
| Market cap | 35.513M |
| Beta (5Y monthly) | 0.24 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.4300 |
| Earnings date | 13 May 2024 - 17 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 25.75 |
GlobeNewswireOcuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual Meeting
FARMINGTON HILLS, Mich., April 22, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP) (“Ocuphire”), a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of retinal and refractive eye disorders, today announced that Daniel Su, M.D. will deliver a paper presentation on oral APX3330 at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting to be held May 5-9, 2024 in Seattle, Washington. Key details about Dr. Su’s pres
- GlobeNewswire
First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery
LYNX-2 Follows SPA Agreement with FDA Development of PS is Funded by Ocuphire’s Partner Viatris FARMINGTON HILLS, Mich., April 11, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of unmet needs of patients with retinal and refractive eye disorders, today announced the enrollment of the first subject in the LYNX-2 Phase 3 registration study evaluating Phentolamine Ophthalmic Solution
- GlobeNewswire
Ocuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris
FARMINGTON HILLS, Mich., April 01, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of unmet needs of patients with retinal and refractive eye disorders, today announced the U.S. commercial launch of RYZUMVI™ (phentolamine ophthalmic solution) by its partner Viatris Inc. (NASDAQ: VTRS). Ocuphire has a global license agreement with Viatris to co-develop and commercialize Phentolamine O
